难治 / 复发急性髓系白血病的 CAR-T 细胞治疗进展
- 天津市第一中心医院血液科,天津市血栓与止血研究所,天津 300192
摘要
急性髓系白血病(AML)是一种起源于造血干/祖细胞的高度异质性血液系统恶性肿瘤,难治/复发AML(R/R AML)指患者对常规诱导化疗无反应,或经治疗达到缓解后白血病细胞再度出现,其预后极差,传统治疗手段效果有限,亟需新的治疗突破。嵌合抗原受体T细胞(CAR-T)疗法作为新型过继性免疫治疗技术,在B细胞恶性肿瘤治疗中取得了突破性进展,但在R/R AML中的应用仍面临靶点特异性不足、抗原逃逸、免疫抑制性肿瘤微环境(TME)及脱靶毒性等核心挑战。近年来,随着对AML生物学特性的深入理解及CAR-T技术的不断创新,针对R/R AML的CAR-T治疗取得了显著进展。本文就R/R AML的CAR-T细胞治疗最新研究进展进行综述。
Progress of CAR - T cell therapy for relapsed / refractory acute myeloid leukemia
- Department of Hematology, Tianjin First Central Hospital, Tianjin Thrombosis and Hemo stasis Institute, Tianjin 300192, China
Abstract
Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy derived from hematopoietic stem/progenitor cells. Refractory/relapsed AML (R/R AML) refers to patients who do not respond to conventional induction chemotherapy, or leukemia cells reappear after achieving remission after treatment. Chimeric antigen receptor T cell (CAR-T) therapy, as a new adoptive immunotherapy technology, has made a breakthrough in B cell malignancies. However, its application in R/R AML still faces core challenges such as insufficient target specificity, antigen escape, immunosuppressive tumor microenvironment (TME), and off-target toxicity. In recent years, with the in-depth understanding of the biological characteristics of AML and the continuous innovation of CAR technology, significant progress has been made in CAR-T therapy for R/R AML. This article reviews the latest research progress of CAR-T cell therapy for R/R AML.
